Santhera Pharmaceuticals Holding's market cap is currently ―. The company's EPS TTM is $-8.947; its P/E ratio is -1.31; Santhera Pharmaceuticals Holding is scheduled to report earnings on April 25, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Dec 21	Jun 21	Dec 20	Jun 20
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	CHF 12.70M	CHF 21.21M	CHF 7.99M	CHF 12.41M	CHF 19.35M
Total Assets	CHF 79.78M	CHF 91.12M	CHF 80.22M	CHF 88.69M	CHF 100.07M
Total Debt	CHF 40.64M	CHF 42.98M	CHF 43.37M	CHF 71.17M	CHF 61.64M
Net Debt	CHF 27.94M	CHF 21.77M	CHF 35.38M	CHF 58.76M	CHF 42.29M
Total Liabilities	CHF 93.63M	CHF 89.79M	CHF 71.86M	CHF 95.04M	CHF 99.86M
Stockholders Equity	CHF -13.85M	CHF 1.33M	CHF 8.35M	CHF -6.35M	CHF 210.00K
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in CHF

Santhera Pharmaceuticals Holding Earnings and Revenue History

Income Statement >

Santhera Pharmaceuticals Holding Debt to Assets

Balance Sheet >

Santhera Pharmaceuticals Holding Cash Flow

Cash Flow >

Santhera Pharmaceuticals Holding Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing